Hansen Medical's Magellan(TM) Robotic System to Be Presented at 40th Annual VEITHsymposium(TM) of Vascular Surgeons & Interve...
13 11월 2013 - 10:00PM
Marketwired
Hansen Medical's Magellan(TM) Robotic System to Be Presented at
40th Annual VEITHsymposium(TM) of Vascular Surgeons and
Interventionalists
MOUNTAIN VIEW, CA--(Marketwired - Nov 13, 2013) - Hansen
Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular
robotics, today announced it will exhibit its Magellan™ Robotic
System at the 40th Annual
VEITHsymposium™ from November 19th-23rd at the Hilton New York
in New York City. The Company will be conducting product
demonstrations and exhibiting the Magellan Robotic System at Booth
201.
Multiple presentations and physician panel sessions discussing
the growing body of compelling clinical data on the Magellan
Robotic System will also be conducted at the conference. In
addition, Hansen Medical will be co-sponsoring a symposium with
Philips Healthcare at noon on Wednesday, November 20th, titled
"Clinical Excellence in the Hybrid OR." Professor
Jean-Pierre Becquemin, M.D. from Henri Mondor Hospital, Cretéil,
France will moderate this session and share his clinical
experiences with the Magellan Robotic System in complex abdominal
aortic aneurysm (AAA) repair procedures. Additionally, Hansen
Medical will be the sole sponsor of a symposium at noon on
Thursday, November 21st, titled "Clinical Experiences with the
Magellan Robotic System." Five speakers (Jean Bismuth,
M.D., Methodist Hospital, Houston; Barry Katzen, M.D., Baptist
Cardiac & Vascular Institute, Miami; Thomas Nolte, M.D., Bad
Bevensen in Germany; Professor Nabil Chakfé, M.D., Hospital Civil
Strasbourg in France; and Professor Nicholas Cheshire, M.D., St.
Mary's Hospital, London) will discuss their clinical experiences
with the Magellan System in a wide variety of endovascular
procedure types.
Hansen Medical also anticipates that the Magellan System will be
featured in the following scheduled presentations:
- Summary of Experience with the Hansen Magellan System for
Robotic Assisted Complex and Routine Endovascular Procedures:
Advantages and Limitations, by Professor Cheshire; Thursday,
November 21st at 2:07 p.m.
- Clinical Experience with Vascular Robotics (Hansen) In
EVAR, Carotid and Other Vascular Applications, by
Dr. Katzen; Thursday, November 21st at 2:12 p.m.
"The VEITHsymposium is one of the year's most important vascular
conferences and we are pleased to have our Magellan System
highlighted prominently in numerous settings throughout the
conference," said Bruce Barclay, President and CEO of Hansen
Medical. "The high level of activity around intravascular
robotics at this meeting is a strong reflection of the continuing
momentum we are seeing both clinically and commercially with the
Magellan System."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used
to facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices. The Magellan System is designed to deliver
predictability to simple and complex endovascular procedures. Since
its commercial introduction in the U.S. and Europe, the Magellan
System has demonstrated its clinical versatility in many cases in a
broad variety of peripheral vascular procedure types in centers
across the US and Europe. The system is based upon the flexible
robotic technology incorporated in the Sensei-X® Robotic
Catheter System currently sold in the U.S. and Europe, which has
been used in more than 10,000 patients, but includes a number of
key enhancements. In particular, the Magellan Robotic System:
- Provides solid catheter stability for placement of
therapeutic devices.
- Is designed to enable predictable procedure times and
increased case throughput.
- Allows for independent, individual robotic control of the
distal tips of both the outer sheath and the inner leader
catheter, as well as robotic manipulation of standard
guidewires.
- Is designed to allow for sufficient extension inside the
body to access hard to reach peripheral anatomy.
- Preserves the open architecture featured in the Sensei
System to allow for the subsequent use of many 6F therapeutic
devices on the market today.
- Is designed to potentially reduce physician radiation
exposure and fatigue by employing a remote physician
workstation.
About Hansen Medical, Inc. Hansen Medical, Inc., based in
Mountain View, California, is a global leader in intravascular
robotics, developing products and technology designed to enable the
accurate positioning, manipulation and control of catheters and
catheter-based technologies. The Company's Magellan™ Robotic
System, 9Fr Magellan™ Robotic Catheter and related accessories,
which are intended to facilitate navigation to anatomical targets
in the peripheral vasculature and subsequently provide a conduit
for manual placement of therapeutic devices, have undergone both CE
marking and 510(k) clearance and are commercially available in the
European Union, and the U.S. In the European Union, the Company's
Sensei® X Robotic Catheter System and Artisan®
and Artisan Extend® Control Catheters are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the
Lynx® Robotic Ablation Catheter is cleared for the
treatment of AF. This robotic catheter system is compatible with
fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S., the Company's Sensei X Robotic
Catheter System and Artisan and Artisan Extend Control Catheters
are cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the U.S., the Sensei X Robotic Catheter System is
not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X Robotic Catheter
System and Artisan and Artisan Extend Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established. Additional information can
be found at www.hansenmedical.com.
Forward-Looking Statements This press release contains
forward-looking statements regarding, among other things,
statements relating to goals, plans, objectives, milestones and
future events. All statements, other than statements of historical
fact, are statements that could be deemed forward-looking
statements, including statements containing the words "plan,"
"expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date
of this press release and are subject to risks, uncertainties,
changes in circumstances and other factors that may cause actual
results to differ materially from the information expressed or
implied by forward-looking statements made in this press release.
Examples of such statements include statements about the potential
benefits of our technology and the value of our intellectual
property portfolio. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for
the sales cycle for newly introduced products; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to maintain our remedial
actions over previously reported material weaknesses in internal
controls over financial reporting; our ability to manage expenses
and cash flow, and obtain additional financing; and other risks
more fully described in the "Risk Factors" section of our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2013 filed
with the SEC on November 8, 2013 and the risks discussed in our
other reports filed with the SEC. Given these uncertainties, you
should not place undue reliance on the forward-looking statements
in this press release. We undertake no obligation to revise or
update information herein to reflect events or circumstances in the
future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial Officer
Hansen Medical, Inc. 650.404.5800 FTI Consulting, Inc. Brian
Ritchie 212.850.5683 Email Contact John Capodanno 212.850.5705
Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024